Cover Image
Market Research Report

Seasonal Influenza Vaccines

Published by Datamonitor Healthcare Product code 365205
Published Content info 123 Pages
Delivery time: 1-2 business days
Price
Back to Top
Seasonal Influenza Vaccines
Published: January 10, 2019 Content info: 123 Pages
Description

OVERVIEW

Seasonal influenza is an acute viral infection that is spread by person-to-person transmission. Influenza, commonly referred to as the flu, circulates worldwide and can affect anyone in any age group, although annual epidemics peak during winter in temperate climates. Seasonal influenza can be type A, B, or C. Type A influenza viruses are considered to be the most virulent of the three types, and can be further classified by serotype based on antibody response to the virus.

MARKET SNAPSHOT

  • Conversion to quadrivalent influenza vaccines will drive market growth.
  • Differentiated vaccines targeting specific population subgroups will see significant uptake.
  • Universal flu vaccines could gain rapid uptake if they can show efficacy against multiple influenza strains.
Table of Contents
Product Code: DMKC10628

TABLE OF CONTENTS

6 FORECAST: SEASONAL INFLUENZA VACCINES (Published on 10 January 2019)

6 OVERVIEW

8 RECENT FORECAST UPDATES

9 MARKET OVERVIEW AND TRENDS

15 KEY DRIVERS AND RESISTORS OF CONVERSION TO QIVS

20 MARKET DEFINITION AND METHODOLOGY

24 US MARKET FORECAST

32 FRANCE MARKET FORECAST

38 GERMANY MARKET FORECAST

43 ITALY MARKET FORECAST

48 SPAIN MARKET FORECAST

53 UK MARKET FORECAST

59 PRIMARY RESEARCH METHODOLOGY

60 MARKETED DRUGS: SEASONAL INFLUENZA VACCINES (Published on 10 January 2019)

60 OVERVIEW

61 PRODUCT OVERVIEW

62 INACTIVATED VACCINES

65 PRODUCT PROFILE: FLUMIST QIV

74 PRODUCT PROFILE: FLUBLOK

81 PRODUCT PROFILE: FLUCELVAX QIV

88 PRODUCT PROFILE: FLUZONE HIGH-DOSE

95 PIPELINE: SEASONAL INFLUENZA VACCINES (Published on 10 January 2019)

95 OVERVIEW

96 CLINICAL PIPELINE OVERVIEW

97 UNIVERSAL INFLUENZA VACCINES

107 ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES

108 PRODUCT PROFILE (LATE STAGE): FLUAD QIV

117 PRODUCT PROFILE (LATE STAGE): MT-2271

LIST OF FIGURES

  • 9 Figure 1: Total sales of seasonal influenza vaccines across the US and five major EU markets, by country, 2017/18-2026/27
  • 16 Figure 2: Total sales of seasonal influenza vaccines across the US and five major EU markets, by class, 2017/18-2026/27
  • 21 Figure 3: Patient-based forecasting methodology for seasonal influenza vaccines
  • 22 Figure 4: Price sources and calculations in the EU, by country
  • 25 Figure 5: Total sales of seasonal influenza vaccines in the US, by class, 2017/18-2026/27
  • 29 Figure 6: Total seasonal influenza vaccination coverage in the US, by risk group, 2017/18-2026/27
  • 33 Figure 7: Total sales of seasonal influenza vaccines in France, by class, 2017/18-2026/27
  • 35 Figure 8: Total seasonal influenza vaccination coverage in France, by risk group, 2017/18-2026/27
  • 39 Figure 9: Total sales of seasonal influenza vaccines in Germany, by class, 2017/18-2026/27
  • 41 Figure 10: Total seasonal influenza vaccination coverage in Germany, by risk group, 2017/18-2026/27
  • 43 Figure 11: Total sales of seasonal influenza vaccines in Italy, by class, 2017/18-2026/27
  • 45 Figure 12: Total seasonal influenza vaccination coverage in Italy, by risk group, 2017/18-2026/27
  • 48 Figure 13: Total sales of seasonal influenza vaccines in Spain, by class, 2017/18-2026/27
  • 50 Figure 14: Total seasonal influenza vaccination coverage in Spain, by risk group, 2017/18-2026/27
  • 53 Figure 15: Total sales of seasonal influenza vaccines in the UK, by class, 2017/18-2026/27
  • 55 Figure 16: Total seasonal influenza vaccination coverage in the UK, by risk group, 2017/18-2026/27

LIST OF TABLES

  • 11 Table 1: Recommendations for influenza vaccination by national authorities, by country, 2018-19
  • 15 Table 2: Key drivers and resistors of conversion to QIVs
  • 23 Table 3: Exchange rates used for calculating prices
  • 27 Table 4: Total influenza coverage rates in the US compared to the five major EU markets, 2017/18-2026/27
  • 61 Table 5: Profiled key marketed vaccines for seasonal influenza
  • 63 Table 6: Inactivated vaccines class overview
  • 64 Table 7: Inactivated vaccines for seasonal influenza - SWOT analysis
  • 66 Table 8: FluMist QIV drug profile
  • 67 Table 9: Approval history of FluMist QIV for seasonal influenza vaccination in the US and five major EU markets
  • 68 Table 10: Late-phase trials of FluMist QIV for seasonal influenza vaccination
  • 69 Table 11: FluMist QIV for seasonal influenza - SWOT analysis
  • 75 Table 12: Flublok drug profile
  • 76 Table 13: Approval history of Flublok for seasonal influenza vaccination
  • 77 Table 14: Late-phase trials of Flublok for seasonal influenza vaccination
  • 78 Table 15: Flublok for seasonal influenza - SWOT analysis
  • 82 Table 16: Flucelvax QIV drug profile
  • 82 Table 17: Approval history of Flucelvax for seasonal influenza vaccination
  • 84 Table 18: Late-phase trials of Flucelvax QIV for seasonal influenza vaccination
  • 85 Table 19: Flucelvax QIV for seasonal influenza - SWOT analysis
  • 89 Table 20: Fluzone High-Dose drug profile
  • 89 Table 21: Approval history of Fluzone HD for seasonal influenza vaccination
  • 91 Table 22: Late-phase trials of Fluzone HD for seasonal influenza vaccination
  • 92 Table 23: Fluzone High-Dose for seasonal influenza - SWOT analysis
  • 96 Table 24: Profiled pipeline products in development for seasonal influenza
  • 98 Table 25: Universal influenza vaccines class overview
  • 100 Table 26: Clinical trials of M-001 for seasonal influenza vaccination
  • 102 Table 27: Clinical trials of Flu-v for seasonal influenza vaccination
  • 104 Table 28: Clinical trials of MVA-NP+M1 for seasonal influenza vaccination
  • 105 Table 29: Universal influenza vaccines for seasonal influenza - SWOT analysis
  • 109 Table 30: Fluad QIV drug profile
  • 111 Table 31: Late-phase trials of Fluad QIV for seasonal influenza vaccination
  • 112 Table 32: Fluad QIV for seasonal influenza - SWOT analysis
  • 118 Table 33: MT-2271 drug profile
  • 119 Table 34: Clinical trials of MT-2271 for seasonal influenza vaccination
  • 120 Table 35: MT-2271 for seasonal influenza - SWOT analysis
Back to Top